Published in Gut Pathog on August 13, 2013
Role of microbiota and innate immunity in recurrent Clostridium difficile infection. J Immunol Res (2014) 0.93
Diet-induced alterations in gut microflora contribute to lethal pulmonary damage in TLR2/TLR4-deficient mice. Cell Rep (2014) 0.88
Antivirulence activity of the human gut metabolome. MBio (2014) 0.88
The microbiota-derived metabolite indole decreases mucosal inflammation and injury in a murine model of NSAID enteropathy. Gut Microbes (2016) 0.86
Phytonutrient diet supplementation promotes beneficial Clostridia species and intestinal mucus secretion resulting in protection against enteric infection. Sci Rep (2015) 0.82
Colonization Resistance of the Gut Microbiota against Clostridium difficile. Antibiotics (Basel) (2015) 0.82
Alcohol and the Intestine. Biomolecules (2015) 0.80
Epigenome-Microbiome crosstalk: A potential new paradigm influencing neonatal susceptibility to disease. Epigenetics (2016) 0.79
Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses. Cancer Prev Res (Phila) (2016) 0.79
Colonization with the enteric protozoa Blastocystis is associated with increased diversity of human gut bacterial microbiota. Sci Rep (2016) 0.79
Groundwater Isolation Governs Chemistry and Microbial Community Structure along Hydrologic Flowpaths. Front Microbiol (2015) 0.78
Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease. Clin Transl Immunology (2016) 0.78
A Clostridium Group IV Species Dominates and Suppresses a Mixed Culture Fermentation by Tolerance to Medium Chain Fatty Acids Products. Front Bioeng Biotechnol (2017) 0.78
Intestinal invalidation of the glucose transporter GLUT2 delays tissue distribution of glucose and reveals an unexpected role in gut homeostasis. Mol Metab (2016) 0.77
Impact of Selection for Digestive Efficiency on Microbiota Composition in the Chicken. PLoS One (2015) 0.77
Impact of a novel protein meal on the gastrointestinal microbiota and the host transcriptome of larval zebrafish Danio rerio. Front Physiol (2015) 0.77
Genome sequencing of multidrug resistant novel Clostridium sp. BL8 reveals its potential for pathogenicity. Gut Pathog (2014) 0.77
Metabolic Interactions in the Gastrointestinal Tract (GIT): Host, Commensal, Probiotics, and Bacteriophage Influences. Microorganisms (2015) 0.76
Steering Endogenous Butyrate Production in the Intestinal Tract of Broilers as a Tool to Improve Gut Health. Front Vet Sci (2015) 0.76
Transcriptional Reprogramming and Resistance to Colonic Mucosal Injury in Poly(ADP-ribose) Polymerase 1 (PARP1)-deficient Mice. J Biol Chem (2016) 0.76
Post-ERCP Emphysematous Cholecystitis in a Young Woman: A Rare and Potentially Fatal Complication. Case Rep Gastrointest Med (2017) 0.75
Variations in the structure of airborne bacterial communities in Tsogt-Ovoo of Gobi desert area during dust events. Air Qual Atmos Health (2016) 0.75
Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model. J Antimicrob Chemother (2016) 0.75
Simultaneous delivery of antibiotics neomycin and ampicillin in drinking water inhibits fermentation of resistant starch in rats. Mol Nutr Food Res (2016) 0.75
Characterization of Gut Microbiome Dynamics in Developing Pekin Ducks and Impact of Management System. Front Microbiol (2017) 0.75
Inbred Mouse Populations Exhibit Intergenerational Changes in Intestinal Microbiota Composition and Function Following Introduction to a Facility. Front Microbiol (2017) 0.75
Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens. Sci Rep (2017) 0.75
Active and Secretory IgA-Coated Bacterial Fractions Elucidate Dysbiosis in Clostridium difficile Infection. mSphere (2016) 0.75
Diversity of the human intestinal microbial flora. Science (2005) 49.64
Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A (2005) 33.66
Metagenomic analysis of the human distal gut microbiome. Science (2006) 29.76
Host-bacterial mutualism in the human intestine. Science (2005) 26.39
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A (2007) 20.60
Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell (2006) 18.83
Induction of colonic regulatory T cells by indigenous Clostridium species. Science (2010) 16.71
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A (2008) 14.18
The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Bacteriol (1994) 11.11
Microbial influences in inflammatory bowel diseases. Gastroenterology (2008) 9.20
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
Gut microbiota in health and disease. Physiol Rev (2010) 7.76
The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett (2002) 7.29
Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev (2001) 7.19
Th17 and regulatory T cells in mediating and restraining inflammation. Cell (2010) 5.89
Peripheral education of the immune system by colonic commensal microbiota. Nature (2011) 5.80
Towards the human intestinal microbiota phylogenetic core. Environ Microbiol (2009) 5.72
Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis. FEMS Microbiol Ecol (2002) 5.44
RNA viral community in human feces: prevalence of plant pathogenic viruses. PLoS Biol (2006) 4.93
Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity (2011) 4.86
Microbes in gastrointestinal health and disease. Gastroenterology (2008) 4.65
Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? Nat Immunol (2004) 4.58
Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev (2006) 4.40
Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut (2000) 4.32
The microbiome in infectious disease and inflammation. Annu Rev Immunol (2012) 3.76
The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol (2009) 3.58
Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett (2004) 3.43
Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med (1989) 3.28
Regulatory T cells reinforce intestinal homeostasis. Immunity (2009) 3.27
Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell (2013) 3.26
Differential roles of segmented filamentous bacteria and clostridia in development of the intestinal immune system. Infect Immun (1999) 3.03
Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol (2007) 3.00
In vivo modulation of cytolytic activity and Thy-1 expression in TCR-gamma delta+ intraepithelial lymphocytes. Science (1989) 2.88
Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol (2010) 2.85
Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis (2009) 2.85
Segmented filamentous bacteria are indigenous intestinal bacteria that activate intraepithelial lymphocytes and induce MHC class II molecules and fucosyl asialo GM1 glycolipids on the small intestinal epithelial cells in the ex-germ-free mouse. Microbiol Immunol (1995) 2.83
A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci U S A (2009) 2.77
Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect Immun (1995) 2.70
p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A (1998) 2.65
Viral diversity and dynamics in an infant gut. Res Microbiol (2008) 2.63
Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil (2012) 2.49
Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev (2004) 2.42
The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin Microbiol Rev (2006) 2.36
Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology (2004) 2.33
Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proc Natl Acad Sci U S A (2010) 2.30
Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol (2005) 2.26
Coordinate regulation of glycan degradation and polysaccharide capsule biosynthesis by a prominent human gut symbiont. J Biol Chem (2009) 2.21
Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest (1995) 2.16
Characterization of clostridia isolated from faeces of limited flora mice and their effect on caecal size when associated with germ-free mice. Lab Anim (1985) 2.12
Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine. Appl Environ Microbiol (2002) 2.08
The gastrointestinal ecosystem: a precarious alliance among epithelium, immunity and microbiota. Cell Microbiol (2001) 2.04
Authentic matrix vesicles contain active metalloproteases (MMP). a role for matrix vesicle-associated MMP-13 in activation of transforming growth factor-beta. J Biol Chem (2001) 1.96
Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut (1993) 1.88
Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev (2011) 1.85
Localization of transforming growth factor beta isoforms in the normal murine small intestine and colon. Gastroenterology (1993) 1.83
New insights in gut microbiota establishment in healthy breast fed neonates. PLoS One (2012) 1.81
Butyrate and glucose metabolism by colonocytes in experimental colitis in mice. Gut (2000) 1.75
Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl (1996) 1.70
Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culture-dependent and -independent analysis of faeces. ISME J (2008) 1.70
Spatial organization of intestinal microbiota in the mouse ascending colon. ISME J (2010) 1.66
Butyrate, aspirin and colorectal cancer. Eur J Cancer Prev (1996) 1.63
Factors controlling the bacterial colonization of the intestine in breastfed infants. Acta Paediatr Suppl (1999) 1.62
Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. Gastroenterology (1993) 1.58
Better living through microbial action: the benefits of the mammalian gastrointestinal microbiota on the host. Environ Microbiol (2009) 1.55
Apoptosis in colorectal tumour cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int J Cancer (1995) 1.54
The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol (2006) 1.50
Intestinal uptake of macromolecules. III. Studies on the mechanism by which immunization interferes with antigen uptake. J Immunol (1975) 1.49
Role of intestinal mucins in innate host defense mechanisms against pathogens. J Innate Immun (2008) 1.45
Bacterial cell-to-cell signaling in the gastrointestinal tract. Infect Immun (2005) 1.43
The immunoregulatory role of dopamine: an update. Brain Behav Immun (2009) 1.42
Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr (2000) 1.40
Aging of the human metaorganism: the microbial counterpart. Age (Dordr) (2011) 1.36
Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis. Gut (1995) 1.26
The effect of age and non-steroidal anti-inflammatory drugs on human intestinal microbiota composition. Br J Nutr (2009) 1.25
The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J (2009) 1.25
Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol (2012) 1.19
Induction of a humoral immune response following an Escherichia coli O157:H7 infection with an immunomodulatory peptidic fraction derived from Lactobacillus helveticus-fermented milk. Clin Diagn Lab Immunol (2004) 1.19
The induction of Treg cells by gut-indigenous Clostridium. Curr Opin Immunol (2012) 1.11
Effect of Bifidobacterium longum ingestion on experimental salmonellosis in mice. J Appl Microbiol (2004) 1.10
The characterization of butyrate transport across pig and human colonic luminal membrane. J Physiol (1998) 1.10
Transforming growth factor-beta enhances interleukin-6 secretion by intestinal epithelial cells. Immunology (1992) 1.06
Lymphocyte subsets in jejunal and ileal Peyer's patches of normal and gnotobiotic minipigs. Immunology (1989) 1.05
Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol (2012) 1.05
Intestinal uptake of macromolecules. IV.--The effect of pancreatic duct ligation on the breakdown of antigen and antigen-antibody complexes on the intestinal surface. Gastroenterology (1975) 1.01
The commensal microbiology of the gastrointestinal tract. Adv Exp Med Biol (2008) 1.00
The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol (2012) 0.98
Overview of the gastrointestinal microbiota. Adv Exp Med Biol (2008) 0.98
Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. Int J Colorectal Dis (2001) 0.95
A mixture containing galactooligosaccharide, produced by the enzymic activity of Bifidobacterium bifidum, reduces Salmonella enterica serovar Typhimurium infection in mice. J Med Microbiol (2009) 0.94
Eradication of Salmonella Typhimurium infection in a murine model of typhoid fever with the combination of probiotic Lactobacillus fermentum ME-3 and ofloxacin. BMC Microbiol (2008) 0.91
Beneficial health effects of low-digestible carbohydrate consumption. Br J Nutr (2001) 0.90
Supplementation of an adapted formula with bovine lactoferrin: 1. Effect on the infant faecal flora. Acta Paediatr (1992) 0.88
An interleukin-7 internet for intestinal intraepithelial T cell development: knockout of ligand or receptor reveal differences in the immunodeficient state. Eur J Immunol (1997) 0.88
Cultivable and pyrosequenced fecal microflora in centenarians and young subjects. J Clin Gastroenterol (2012) 0.85
Host-microbe communication within the GI tract. Adv Exp Med Biol (2008) 0.82
Intestinal Lactobacillus sp. is associated with some cellular and metabolic characteristics of blood in elderly people. Anaerobe (2010) 0.81
Effects of age and region on fecal microflora in elderly subjects living in Bama, Guangxi, China. Curr Microbiol (2010) 0.79
Luminal adrenergic agents modulate ileal transport: discrimination between alpha 1 and alpha 2 receptors. Am J Surg (1994) 0.78
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 3.32
Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res (2013) 2.84
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2014) 2.47
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology (2006) 2.35
Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol (2014) 2.21
Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol (2009) 2.17
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol (2009) 2.14
Different Antibiotic No Culture Eradicating (DANCE) strategy: an easy way to manage H. pylori eradication. Dig Liver Dis (2012) 2.11
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol (2005) 1.82
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol (2010) 1.69
Acute cryptogenic liver failure in an untreated coeliac patient: a case report. Eur J Gastroenterol Hepatol (2005) 1.65
Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol (2006) 1.62
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol (2013) 1.62
The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord (2013) 1.62
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
Endometriosis, need for a multidisciplinary clinical setting: the internist's point of view. Intern Emerg Med (2010) 1.53
Image-enhanced endoscopy with I-scan technology for the evaluation of duodenal villous patterns. Dig Dis Sci (2012) 1.52
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis. J Clin Gastroenterol (2003) 1.48
The European experience with double-balloon enteroscopy: indications, methodology, safety, and clinical impact. Gastrointest Endosc (2005) 1.41
Bacillus subtilis isolated from the human gastrointestinal tract. Res Microbiol (2008) 1.38
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2012) 1.35
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol (2002) 1.32
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol (2005) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats. Gastroenterology (2007) 1.17
CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis (2008) 1.15
Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol (2003) 1.15
Extragastric diseases and Helicobacter pylori. Helicobacter (2013) 1.14
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer (2014) 1.13
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer (2013) 1.12
Helicobacter pylori and extragastric diseases. Best Pract Res Clin Gastroenterol (2007) 1.12
Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair (2012) 1.11
Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation (2002) 1.11
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2010) 1.11
Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget (2011) 1.11
Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol (2010) 1.11
Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol (2007) 1.09
Sequential or combined treatment? That is the question. Radiology (2014) 1.07
Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol (2008) 1.05
Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol (2009) 1.05
Regional cerebral hypoperfusion in patients with celiac disease. Am J Med (2004) 1.03
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2011) 1.02
Therapeutic implications of mesenchymal stem cells in liver injury. J Biomed Biotechnol (2011) 1.02
Isolation and characterization of hepatic stem cells, or "oval cells," from rat livers. Methods Mol Biol (2009) 1.02
Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab (2007) 1.01
Autoimmune enteropathy in children and adults. Scand J Gastroenterol (2009) 1.00
Gut microbiota and obesity. Intern Emerg Med (2010) 1.00
Helicobacter pylori, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients. Pediatrics (2003) 1.00
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2012) 0.99
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology (2013) 0.99
Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol (2002) 0.99
The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol (2012) 0.98
The role of methane in intestinal diseases. Am J Gastroenterol (2010) 0.98
Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion (2004) 0.98
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. Am J Gastroenterol (2003) 0.97
Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol (2009) 0.97
Coronary atherosclerotic burden in patients with infection by CagA-positive strains of Helicobacter pylori. Coron Artery Dis (2010) 0.96
Management and treatment of lactose malabsorption. World J Gastroenterol (2006) 0.96
Clinical use of albumin in hepatology. Blood Transfus (2009) 0.96
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int (2013) 0.95
Colon cancer stem cells: controversies and perspectives. World J Gastroenterol (2013) 0.95
Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr Pharm Des (2013) 0.95
Extragastric manifestations of Helicobacter pylori infection -- other Helicobacters. Helicobacter (2007) 0.95
CagA-positive cytotoxic H. pylori strains as a link between plaque instability and atherosclerotic stroke. Eur Heart J (2004) 0.95
Helicobacters and extragastric diseases. Helicobacter (2009) 0.95
Association between migraine and Celiac disease: results from a preliminary case-control and therapeutic study. Am J Gastroenterol (2003) 0.94
The role of H. pylori infection in diabetes. Curr Diabetes Rev (2005) 0.94
Ipilimumab Adjuvant Therapy in Melanoma. N Engl J Med (2017) 0.94
Use of Liver Imaging and Biopsy in Clinical Practice. N Engl J Med (2017) 0.94
Anti-tissue transglutaminase antibodies from celiac patients are responsible for trophoblast damage via apoptosis in vitro. Am J Gastroenterol (2010) 0.94
Helicobacter pylori and extragastric diseases. Helicobacter (2014) 0.94
Reliability of the "immersion technique" during routine upper endoscopy for detection of abnormalities of duodenal villi in patients with dyspepsia. Gastrointest Endosc (2004) 0.93
Emerging technologies in upper gastrointestinal endoscopy and celiac disease. Nat Clin Pract Gastroenterol Hepatol (2008) 0.93
Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in Apc(Min/+) mice. Clin Cancer Res (2010) 0.92
Neurotrophic features of human adipose tissue-derived stromal cells: in vitro and in vivo studies. J Biomed Biotechnol (2011) 0.92
The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs (2009) 0.92
High prevalence of celiac disease in patients with lactose intolerance. Digestion (2005) 0.91
Role of probiotics in patients with Helicobacter pylori infection. Helicobacter (2007) 0.91
Direct visualization of intestinal villi by high-resolution magnifying upper endoscopy: a validation study. Gastrointest Endosc (2004) 0.91
High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int J Antimicrob Agents (2004) 0.91
Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? World J Gastroenterol (2010) 0.91
Gut microbiota and metabolic syndrome. Intern Emerg Med (2013) 0.91
Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. Dig Dis (2008) 0.90
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. J Crohns Colitis (2012) 0.90
Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients? Expert Opin Pharmacother (2010) 0.90
Biological therapies for inflammatory bowel disease: research drives clinics. Mini Rev Med Chem (2006) 0.90
Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology (Oxford) (2013) 0.90
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig Dis (2008) 0.90
High prevalence of Cag-A positive H. pylori strains in ischemic stroke: a primary care multicenter study. Helicobacter (2008) 0.89
Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore) (2014) 0.89
Gene profiling of bone marrow- and adipose tissue-derived stromal cells: a key role of Kruppel-like factor 4 in cell fate regulation. Cytotherapy (2010) 0.89